+49 761-389 49-0
The use of ctDNA in the study and treatment of cancer continues to expand. Recent advances have highlighted CpG methylation of ctDNA a biomarker with multiple utilities. Methylation status gives insight to tumor recurrence, epigenetic regulation of gene expression and may also indicate tissue of origin of ctDNA.
Despite the impactful layer of information methylation status adds to base-pair level sequencing data and the proliferation of assays to incorporate methylation data, reference materials have been limited compared to other areas of oncology.Seraseq Methylated ctDNA Mutation Mix is a low background ctDNA reference material comprised of ctDNA that is methylated (>90% detectable methylation) at all CpG sites. It can be used on its own or blended with Seraseq unmethylated ctDNA Mutation Mix to create a desired percent methylated ctDNA profile.
FEATURES•Global methylation of CpG sites to support all CpG methylation assays
•Methylated ctDNA and unmethylated ctDNA to blend to a desiredpercent methylated ctDNA
•Enzymatically fragmented ctDNA for low background noise and physiologicallyrelevant fragment sizes
•Methylation status precisely quantified using highly sensitive digital PCR assays
in a well-characterized genomic background (GM24385)
•Validated by targeted NGS panels
•Manufactured in GMP-compliant, ISO 13485-certified facilitiesGene Percent Methylation- Unmethylated Percent Methylation- Methylated
